Recursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the target of unusually large options trading activity on Thursday. Stock investors bought 52,856 call options on the stock. This is an increase of approximately 134% compared to the average volume of 22,543 call options.

Wall Street Analysts Forecast Growth

RXRX has been the topic of several analyst reports. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday. Morgan Stanley started coverage on shares of Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.25.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the firm’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the transaction, the insider owned 668,197 shares of the company’s stock, valued at $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 8.43% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. ARK Investment Management LLC increased its stake in Recursion Pharmaceuticals by 7.6% in the first quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company’s stock valued at $184,174,000 after acquiring an additional 2,469,104 shares during the period. Softbank Group CORP. bought a new stake in Recursion Pharmaceuticals in the 4th quarter valued at $99,152,000. Kinnevik AB publ increased its stake in Recursion Pharmaceuticals by 12.8% in the 1st quarter. Kinnevik AB publ now owns 13,434,171 shares of the company’s stock valued at $71,067,000 after buying an additional 1,528,503 shares during the last quarter. Geode Capital Management LLC increased its stake in Recursion Pharmaceuticals by 20.7% in the 2nd quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock valued at $39,353,000 after buying an additional 1,332,428 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Recursion Pharmaceuticals by 183.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock valued at $33,901,000 after buying an additional 4,149,346 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Up 6.8%

Shares of NASDAQ:RXRX opened at $4.85 on Friday. The firm has a fifty day moving average of $5.35 and a two-hundred day moving average of $5.35. The firm has a market capitalization of $2.11 billion, a P/E ratio of -2.72 and a beta of 0.91. Recursion Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $12.36. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The business had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. During the same period in the previous year, the firm posted ($0.40) EPS. The firm’s revenue for the quarter was up 33.3% on a year-over-year basis. On average, equities analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.